Sungening has 4 candidates now available for out-licensing. Including two small molecular compounds SG1001 and SG834, for the treatment of invasive Aspergillums and solid tumors, respectively. And two cyclic peptide compounds SG5035 and SG6001, for the treatment of invasive Candidiasis and hyperlipidemia, respectively. The target product profiles of them are listed below for reference.

Parameters	Profile
Indications	Invasive Aspergillums
Patient Population	Adults with limited or no treatment options, including aspergilllosis, or pulmonary invasive aspergillosis
Therapeutic Modality	Small Molecular
Dosage form	Tablets
Administration	Oral, once daily
Mechanism of Action	Inhibition of fungal enzyme dihydroorotate dehydrogenase (DHODH) resulting in the disruption of pyrimidine biosynthesis, ultimately leading to the inhibition of fungal growth and proliferation.
Biological Activity	The minimum inhibitory concentration (MIC) values for SG1001 against various Aspergillums species are comparable or even lower than those of currently available antifungal agents, indicating it is highly active against these common fungal pathogens.

Parameters	Profile
Indications	Invasive candidiasis
Patient Population	Patients with invasive candidiasis or who have failed to respond to standard antifungal treatments or have developed resistance to these common agents
Therapeutic Modality	Cyclic Peptides
Dosage form	Solution in prefilled syringe
Administration	Subcutaneous injections, once every 2 weeks
Mechanism of Action	Inhibition of beta-1,3-D-glucan synthase resulting in the disruption the normal synthesis of the fungal cell wall, leading to its weakening and subsequent lysis, ultimately leading to the death of the fungal cell
Biological Activity	The MIC value shown by SG5035 is comparable to or even lower than that of currently available echinocinins antifungal drugs, and its half-life in animals is long, indicating that it has ultra-long-term antibacterial activity against common fungal pathogens.

Parameters	Profile
Indications	Hyperlipidemia(hypercholesterolemia and atherosclerotic cardiovascular disease)
Patient Population	Patient Population Patients who are intolerant to statins, those with familial hyperlipidemia and those who are afraid of needles
Therapeutic Modality	Cyclic Peptides
Dosage form	Tablets
Administration	Oral, daily
Mechanism of Action	Proprotein convertase subtilisin/kexin type 9 (PCSK9) is prone to bind to LDL-R, thereby affecting the binding of LDL-R and LDL-C. After inhibiting PCSK9, the circulation of LDL-R will be restored, reducing the level of LDL-C in the blood and thus achieving the purpose of lipid reduction.
Biological Activity	The inhibition constant KI value reaches the pM level, indicating that SG6001 has an extremely strong affinity for PCSK9, making it an efficient oral PCSK9 inhibitor.

Parameters	Profile
Indications	Solid tumor
Patient Population	Patient with advanced solid tumor such as squamous non-small-cell lung cancer, triple negative breast cancer, gastric adenocarcinoma, colorectal adenocarcinoma
Therapeutic Modality	Small Molecular
Dosage form	Tablets
Administration	Oral, daily
Mechanism of Action	Tumor synthetic lethal involved, the combination of KIF18A inhibitor and chromosomal instability (CIN) in cancer cell resulting in the disruption of microtubule dynamics and mitotic spindle formation, leading to cell death
Biological Activity	With an IC50 value of 0.0098 μM. This low IC50 value indicates that SG834 effectively binds to and inhibits KIF18A at low concentrations, making it a highly potent inhibitor

        If you are interested in our pipelines, please contact us